Evidence map›Paper›PMID 40895531›Full record

ArticleFrontiers in immunology2025

Comparative analysis of CDR3 length-dependent patterns in VHHs.

Lu Zhang, Tianyu Yang, Yao Zhang, Jiahui Yan, Jiaguo Li, Wenfeng Xu, Weimin Zhu, Xinhao Wang

Abstract readComparative Study
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lu Zhang *Drug Discovery and Development, Shanghai Cell Therapy Group Co. Ltd., Shanghai, China.
Tianyu Yang *Drug Discovery and Development, Shanghai Cell Therapy Group Co. Ltd., Shanghai, China.
Yao ZhangDrug Discovery and Development, Shanghai Cell Therapy Group Co. Ltd., Shanghai, China.
Jiahui YanDrug Discovery and Development, Shanghai Cell Therapy Group Co. Ltd., Shanghai, China.
Jiaguo LiDrug Discovery and Development, Shanghai Cell Therapy Group Co. Ltd., Shanghai, China.
Wenfeng XuDrug Discovery and Development, Chantibody Therapeutics, Menlo Park, CA, United States.
Weimin ZhuDrug Discovery and Development, Shanghai Cell Therapy Group Co. Ltd., Shanghai, China.
Xinhao WangDrug Discovery and Development, Chantibody Therapeutics, Menlo Park, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: VHHs, or nanobodies, are distinguished by their compact size, high stability, and unique ability to selectively target specific epitopes. The CDR3 region in VHHs, which plays a crucial role in antigen binding, exhibits significant diversity and varies among species. Method: This study systematically examined CDR3 length dependent patterns by analyzing NGS sequences from the PBMCs of Alpacas, Llamas and Bactrians, in conjunction with VHH structure data from the public database. Results: VHHs from Alpacas and Llamas exhibited similar CDR3 length distributions, while Bactrian VHHs displayed significantly longer but narrower length distribution. Key sequence, structural, and VHH/antigen interaction characteristics correlated with CDR3 length were identified. Specifically, longer CDR3s were associated with a lower net charge, reduced surface hydrophobicity, and enhanced interactions with other VHH regions. Structural analyses revealed that longer CDR3s tended to adopt bent conformations with increased helical and coil structures, whereas shorter CDR3s favored extended conformations and β-sheets. Associations between CDR3 length and amino acid usage patterns within VHH sequences were also observed, including preferences at various sites and in antigen interactions. Notably, species-specific differences were apparent, with Alpaca and Llama VHHs showing more pronounced CDR3 length-dependent patterns than those from Bactrians. Discussion: These findings highlight the significant impact of CDR3 length on VHH sequence, structure, and antigen interaction characteristics, providing valuable insights for VHH engineering, synthetic library design, and the development of therapeutic nanobodies optimized for targeting diverse epitopes.

Indexed as

Complementarity Determining RegionsImmunoglobulin Heavy ChainsSingle-Domain AntibodiesAmino Acid SequenceAnimalsCamelids, New WorldComplementarity Determining RegionsImmunoglobulin Heavy ChainsSingle-Domain AntibodiesCDR3CDR3 lengthepitopenanobodyparatopesingle-domain antibodyVHHVHH-Ag interaction

Identifiers

PMID40895531
PMCPMC12394203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.